Humam Kadara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8606373/publications.pdf

Version: 2024-02-01

117625 123424 4,216 77 34 61 h-index citations g-index papers 85 85 85 6599 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	OBIF: an omics-based interaction framework to reveal molecular drivers of synergy. NAR Genomics and Bioinformatics, 2022, 4, lqac028.	3.2	5
2	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	7.0	9
3	Chronic Exposure to Waterpipe Smoke Elicits Immunomodulatory and Carcinogenic Effects in the Lung. Cancer Prevention Research, 2022, 15, 423-434.	1.5	1
4	Targeting IL- $1\hat{l}^2$ as an immunopreventive and therapeutic modality for K-rasâ \in "mutant lung cancer. JCI Insight, 2022, 7, .	5.0	25
5	Cell-by-Cell: Unlocking Lung Cancer Pathogenesis. Cancers, 2022, 14, 3424.	3.7	3
6	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	2.6	10
7	Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 90-101.	5 . 6	22
8	Tideglusib attenuates growth of neuroblastoma cancer stem/progenitor cells in vitro and in vivo by specifically targeting GSK- $3\hat{1}^2$. Pharmacological Reports, 2021, 73, 211-226.	3. 3	19
9	Whole Transcriptome Sequencing Analysis of Cancer Stem/Progenitor Cells Obtained from Mouse Lung Adenocarcinomas. Methods in Molecular Biology, 2021, 2279, 187-198.	0.9	0
10	Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon. SAGE Open Medicine, 2021, 9, 205031212110437.	1.8	1
11	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	12.8	30
12	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	30.7	357
13	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	3.7	7
14	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	1.1	62
15	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discovery, 2021, 11, 2506-2523.	9.4	68
16	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	12.8	74
17	Early Diagnosis and Screening for Lung Cancer. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a037994.	6.2	13
18	Cytokine/Chemokine Release Patterns and Transcriptomic Profiles of LPS/IFNÎ ³ -Activated Human Macrophages Differentiated with Heat-Killed Mycobacterium obuense, M-CSF, or GM-CSF. International Journal of Molecular Sciences, 2021, 22, 7214.	4.1	3

#	Article	IF	CITATIONS
19	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	1.1	34
20	Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy. Clinical Cancer Research, 2021, 27, 5878-5890.	7.0	30
21	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	12.8	42
22	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76
23	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	4.2	14
24	Field Carcinogenesis in Cancer Evolution: What the Cell Is Going On?. Cancer Research, 2020, 80, 4888-4891.	0.9	15
25	Circulating Tumor Cell Detection Technologies and Clinical Utility: Challenges and Opportunities. Cancers, 2020, 12, 1930.	3.7	128
26	Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets. PLoS ONE, 2020, 15, e0237442.	2.5	24
27	Anti-Tumor Effects of Biomimetic Sulfated Glycosaminoglycans on Lung Adenocarcinoma Cells in 2D and 3D In Vitro Models. Molecules, 2020, 25, 2595.	3.8	9
28	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Frontiers in Immunology, 2020, 11, 159.	4.8	73
29	Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer. Carcinogenesis, 2020, 41, 1529-1542.	2.8	9
30	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	4.2	21
31	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	12.8	140
32	Sex differences in gene expression with galactosylceramide treatment in Cln3î"ex7/8 mice. PLoS ONE, 2020, 15, e0239537.	2.5	3
33	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	12.8	91
34	Deep targeted sequencing analysis of hot spot mutations in non-small cell lung cancer patients from the Middle Eastern population. Journal of Thoracic Disease, 2019, 11, 2383-2391.	1.4	3
35	Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 742-750.	5.6	20
36	Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine, 2019, 42, 296-303.	6.1	15

#	Article	IF	Citations
37	Epigenetic Suppression of the T-box Subfamily 2 (TBX2) in Human Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 1159.	4.1	19
38	Genome-Wide and Phenotypic Evaluation of Stem Cell Progenitors Derived From Gprc5a-Deficient Murine Lung Adenocarcinoma With Somatic Kras Mutations. Frontiers in Oncology, 2019, 9, 207.	2.8	11
39	Genome-Wide Gene Expression Changes in the Normal-Appearing Airway during the Evolution of Smoking-Associated Lung Adenocarcinoma. Cancer Prevention Research, 2018, 11, 237-248.	1.5	23
40	Distinct pattern of <i>TP53</i> mutations in human immunodeficiency virus–related head and neck squamous cell carcinoma. Cancer, 2018, 124, 84-94.	4.1	22
41	<i>SLURPâ€1</i> is mutated in Mal de Meleda, a potential molecular signature for melanoma and a putative squamous lineage tumor suppressor gene. International Journal of Dermatology, 2018, 57, 162-170.	1.0	23
42	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nature Communications, 2018, 9, 4589.	12.8	57
43	Transcriptomic Alterations in Lung Adenocarcinoma Unveil New Mechanisms Targeted by the TBX2 Subfamily of Tumor Suppressor Genes. Frontiers in Oncology, 2018, 8, 482.	2.8	23
44	IL22 Promotes <i>Kras</i> -Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties. Cancer Immunology Research, 2018, 6, 788-797.	3.4	59
45	Strategies for identification of somatic variants using the lon Torrent deep targeted sequencing platform. BMC Bioinformatics, 2018, 19, 5.	2.6	24
46	Requirement for MUC5AC in KRAS-dependent lung carcinogenesis. JCI Insight, 2018, 3, .	5.0	25
47	Genomics of adult and pediatric solid tumors. American Journal of Cancer Research, 2018, 8, 1356-1386.	1.4	14
48	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 5489-5501.	7.0	55
49	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Research, 2017, 77, 6119-6130.	0.9	92
50	Development of <i>Kras</i> mutant lung adenocarcinoma in mice with knockout of the airway lineageâ€specific gene <scp><i>G</i></scp> <i>prc5a</i> . International Journal of Cancer, 2017, 141, 1589-1599.	5.1	33
51	Germline and Somatic Smoothened Mutations in Non–Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precision Oncology, 2017, 1, 1-10.	3.0	3
52	Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria. Frontiers in Immunology, 2017, 8, 1253.	4.8	7
53	Smoking and Lung Cancer: A Geo-Regional Perspective. Frontiers in Oncology, 2017, 7, 194.	2.8	49
54	<i>TBX2</i> subfamily suppression in lung cancer pathogenesis: a high-potential marker for early detection. Oncotarget, 2017, 8, 68230-68241.	1.8	25

#	Article	IF	Citations
55	Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Research, 2016, 76, 3676-3683.	0.9	35
56	IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras–Mutant Lung Cancer. Cancer Research, 2016, 76, 3189-3199.	0.9	165
57	Early Events in the Molecular Pathogenesis of Lung Cancer. Cancer Prevention Research, 2016, 9, 518-527.	1.5	82
58	Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients. Clinical Cancer Research, 2016, 22, 6278-6289.	7.0	130
59	Radiotherapeutic bandage for the treatment of squamous cell carcinoma of the skin. Nuclear Medicine and Biology, 2016, 43, 333-338.	0.6	18
60	LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-mediated stress response pathway in lung cancer cells. Scientific Reports, 2015, 5, 13846.	3.3	15
61	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	9.4	696
62	Transcriptomic Architecture of the Adjacent Airway Field Cancerization in Non–Small Cell Lung Cancer. Journal of the National Cancer Institute, 2014, 106, dju004.	6.3	72
63	ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 3383-3395.	7.0	146
64	Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling. Cancer Prevention Research, 2013, 6, 8-17.	1.5	36
65	Field Cancerization in Non–Small Cell Lung Cancer. Proceedings of the American Thoracic Society, 2012, 9, 38-42.	3.5	78
66	g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012, 7, 1747-1754.	1.1	51
67	Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer, 2012, 118, 2889-2899.	4.1	91
68	Pulmonary adenocarcinoma: A renewed entity in 2011. Respirology, 2012, 17, 50-65.	2.3	65
69	Abnormalities of the $\langle i \rangle$ TITF- $1 \langle i \rangle$ Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis. Clinical Cancer Research, 2011, 17, 2434-2443.	7.0	74
70	A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis. Clinical Cancer Research, 2011, 17, 1490-1501.	7.0	63
71	A Gprc5a Tumor Suppressor Loss of Expression Signature Is Conserved, Prevalent, and Associated with Survival in Human Lung Adenocarcinomas. Neoplasia, 2010, 12, 499-IN8.	5.3	32
72	Sex Determining Region Y-Box 2 (SOX2) Is a Potential Cell-Lineage Gene Highly Expressed in the Pathogenesis of Squamous Cell Carcinomas of the Lung. PLoS ONE, 2010, 5, e9112.	2.5	117

#	Article	IF	CITATION
73	Comparative Functional Genomics Analysis of NNK Tobacco-Carcinogen Induced Lung Adenocarcinoma Development in Gprc5a-Knockout Mice. PLoS ONE, 2010, 5, e11847.	2.5	41
74	Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an <i>In vitro</i> Lung Carcinogenesis System. Cancer Prevention Research, 2009, 2, 702-711.	1.5	56
75	Involvement of Rac in Fenretinide-Induced Apoptosis. Cancer Research, 2008, 68, 4416-4423.	0.9	23
76	Induction of endoplasmic reticulum stress by the pro-apoptotic retinoid N-(4-Hydroxyphenyl)retinamide via a reactive oxygen species-dependent mechanism in human head and neck cancer cells. Cancer Biology and Therapy, 2007, 6, 705-711.	3.4	42
77	Induction of GDF-15/NAG-1/MIC-1 in human lung carcinoma cells by retinoid-related molecules and assessment of Its role in apoptosis. Cancer Biology and Therapy, 2006, 5, 518-522.	3.4	34